

# Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures *NPM1/FLT3-ITD/-TKD* mutant acute myeloid leukemia in a patient-derived xenograft model

Bing Z. Carter,<sup>1</sup> Po Yee Mak,<sup>1\*</sup> Wenjing Tao,<sup>1\*</sup> Lauren B. Ostermann,<sup>1</sup> Duncan H. Mak,<sup>1</sup> Baozhen Ke,<sup>1</sup> Peter Ordentlich,<sup>2</sup> Gerard M. McGeehan,<sup>2</sup> and Michael Andreeff<sup>1</sup>

<sup>1</sup>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX and <sup>2</sup>Syndax, Waltham, MA, USA

*\*PYM and WT contributed equally as second authors.*

Correspondence:

B.Z. CARTER - bicarter@mdanderson.org

M. ANDREEFF - mandreef@mdanderson.org


<https://doi.org/10.3324/haematol.2022.281927>

Supplemental data to Letter to the Editor:

Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures *NPM1/FLT3-ITD/-TKD* mutant acute myeloid leukemia in a patient-derived xenograft model

Bing Z. Carter,<sup>1</sup> Po Yee Mak,<sup>1</sup> Wenjing Tao,<sup>1</sup> Lauren B. Ostermann,<sup>1</sup> Duncan H. Mak,<sup>1</sup> Baozhen Ke,<sup>1</sup> Peter Ordentlich,<sup>2</sup> Gerard M. McGeehan,<sup>2</sup> and Michael Andreeff<sup>1</sup>

Supplemental Figure 1



Supplemental Figure 1. Mouse body weights before and during treatment.

## Supplemental Table 1. Characteristics of patients

number	source	Blast	cytogenetics	mutations	previous treatments and responses
1	PB	85%	46,XY[6]	<i>NPM1, FLT3-ITD, DNMT3A; IDH2</i>	Resistance to ASTX727, Venetolax and Gilteritinib.
2	PB	95%	46,XY[20]	<i>NPM1, FLT3-ITD/TKD, WT1, DNMT3A</i>	Resistance to Busulfan, Fludarabine and Cladribine, Azacitidine, Venetoclax, Gilteritinib, Cladribine with Idarubicin and Cytarabine (CLIA) plus Gilteritinib.
3	PB	94%	46,XX[1]	<i>NPM1, FLT3-ITD, GATA1, DNMT3A, SMC3, TET2, WT1</i>	Relapsed/Refractory AML. Resistance to 7+3 and GO, High dose Ara-C and midostaurin and azacitidine/venetoclax.
4	PB	93%	Diploid male karyotype 46,XY[14] 2 metaphases photographed/karyotyped	<i>NPM1, FLT3-ITD/TKD, IDH1, DNMT3A</i>	Resistance to 3 + 7 chemotherapy and MEC plus HiDAC consolidation.

**Supplemental Table 2.** Leukemia cells in mouse BM, spleen, and PB of 3-drug and 4-drug combination treatment groups at death determined by flow cytometric measurement of human CD45 positivity.

Treatment group	Survival days	huCD45+ (%)			Histology	death
		BM	Spleen	PB		
SNDX+VEN+Gil	162	63.5	93.5			moribund
	171					found dead
	195	22.7	49.9			moribund
	274					found dead
	414	0	0	0		sac due to age
	414	0	0	0		sac due to age
SNDX+VEN+Gil+5AZA	189					found dead
	258	0.06	0.15		yes	moribund
	414	0	0	0		sac due to age
	414	<0.001	0	0		sac due to age
	414	0	0	0		sac due to age

huCD45, human CD45; PB, peripheral blood; SNDX, SNDX-50469; VEN, venetoclax; Gil, gilteritinib; 5AZA, 5-azacytidine.